Infectious Disease Research Program, Department of Pediatric Hematology and Oncology and Center for Bone Marrow Transplantation, University Children's Hospital Muenster, Germany.
Department of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands.
Clin Infect Dis. 2019 May 2;68(Suppl 4):S260-S274. doi: 10.1093/cid/ciz076.
Since its introduction in the 1990s, liposomal amphotericin B (LAmB) continues to be an important agent for the treatment of invasive fungal diseases caused by a wide variety of yeasts and molds. This liposomal formulation was developed to improve the tolerability of intravenous amphotericin B, while optimizing its clinical efficacy. Since then, numerous clinical studies have been conducted, collecting a comprehensive body of evidence on its efficacy, safety, and tolerability in the preclinical and clinical setting. Nevertheless, insights into the pharmacokinetics and pharmacodynamics of LAmB continue to evolve and can be utilized to develop strategies that optimize efficacy while maintaining the compound's safety. In this article, we review the clinical pharmacokinetics, pharmacodynamics, safety, and efficacy of LAmB in a wide variety of patient populations and in different indications, and provide an assessment of areas with a need for further clinical research.
自 20 世纪 90 年代问世以来，脂质体两性霉素 B（LAmB）仍然是治疗由各种酵母和霉菌引起的侵袭性真菌感染的重要药物。这种脂质体制剂的开发旨在提高静脉内两性霉素 B 的耐受性，同时优化其临床疗效。此后，进行了许多临床研究，收集了大量关于其在临床前和临床环境中的疗效、安全性和耐受性的证据。然而，对 LAmB 的药代动力学和药效学的认识仍在不断发展，可以利用这些认识来制定策略，在保持化合物安全性的同时优化疗效。在本文中，我们综述了 LAmB 在各种患者人群和不同适应证中的临床药代动力学、药效学、安全性和疗效，并评估了需要进一步临床研究的领域。
